Last updated: September 7, 2026
Teriflunomide, marketed by Sanofi as Aubagio, transitioned from a high-value multiple sclerosis product to a generic-exposed medicine after U.S. patent and regulatory exclusivity barriers weakened in 2023. Sanofi’s Aubagio revenue fell sharply after generic launches, while the active ingredient retained substantial clinical demand through lower-cost generic versions. The product’s long-term commercial value is now concentrated in generic volume, international markets, and treatment access rather than branded pricing.
What is teriflunomide and how is it used?
Teriflunomide is an oral immunomodulatory therapy for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. It inhibits dihydro-orotate dehydrogenase, reducing pyrimidine synthesis and limiting proliferation of activated lymphocytes.
| Product characteristic |
Teriflunomide |
| Original brand |
Aubagio |
| Originator |
Sanofi |
| Dosage forms |
7 mg and 14 mg tablets |
| Route |
Oral |
| Initial U.S. approval |
September 2012 |
| Primary indication |
Relapsing forms of multiple sclerosis |
| FDA regulatory category |
New molecular entity, small molecule |
| Main competitors |
Dimethyl fumarate, fingolimod, ocrelizumab, ofatumumab, interferon beta products |
| Main commercial risk |
Generic substitution and price erosion |
Aubagio differentiated itself through once-daily oral dosing. Its clinical limitations include hepatotoxicity concerns, teratogenic risk, possible hypertension, alopecia, gastrointestinal adverse events, and the need for monitoring and accelerated elimination procedures in certain patients. The safety profile constrained use in some patients relative to newer high-efficacy therapies.
How did teriflunomide sales develop before generic entry?
Aubagio became one of Sanofi’s largest specialty products during the 2010s and early 2020s. Its growth was supported by oral administration, established physician familiarity, and expansion of multiple sclerosis treatment in international markets.
Public Sanofi reporting shows that Aubagio generated approximately €2 billion annually before the U.S. loss of exclusivity. Sanofi reported Aubagio sales of roughly €2.1 billion in 2022, followed by a material decline in 2023 as generic competition entered the United States.[1][2]
| Fiscal year |
Approximate Aubagio sales |
Commercial interpretation |
| 2019 |
About €2.0 billion |
Mature branded product |
| 2020 |
About €2.0 billion |
Stable demand during late-cycle exclusivity |
| 2021 |
About €2.0 billion |
Continued global contribution |
| 2022 |
About €2.1 billion |
Peak or near-peak branded exposure |
| 2023 |
About €1.3 billion |
Decline following U.S. generic entry |
| 2024 onward |
Expected to remain materially lower |
Generic erosion and international residual sales |
Reported figures vary by Sanofi reporting period, currency translation, and whether sales are presented as reported or at constant exchange rates. The direction is consistent: Aubagio revenue remained resilient through 2022 and declined rapidly after generic availability.
When did teriflunomide lose exclusivity?
U.S. commercial exclusivity developed in stages rather than on one date.
| Exclusivity or IP milestone |
Date or period |
Effect |
| FDA approval of Aubagio |
September 2012 |
Commercial launch |
| Five-year new chemical entity exclusivity |
Approximately September 2017 |
Blocked ANDA approval during the NCE period, subject to statutory exceptions |
| Core composition patent expiry |
2023 |
Removed the principal long-term patent barrier |
| Generic approvals and launches |
2023 |
Enabled direct generic substitution |
| Pediatric exclusivity |
Potentially extended relevant FDA protection by six months if awarded |
Limited incremental protection; did not preserve the branded franchise after generic entry |
The principal U.S. composition patent commonly associated with teriflunomide and Aubagio is U.S. Patent No. 7,332,521. Public patent records identify an expiration period in 2023, subject to patent-term adjustments and applicable regulatory extensions.[3] Orange Book listings and court records should be read together because a listed patent’s expiration date, pediatric extension, and enforceability can produce different commercial outcomes.[4]
What patents protect teriflunomide and Aubagio?
The strongest historical protection came from patents covering teriflunomide and related chemical matter. Later patents addressed dosing, formulations, and treatment methods, but secondary patents generally offered less reliable protection against generic entry than the core composition patent.
| Patent category |
Commercial purpose |
Relative protection |
| Composition-of-matter patents |
Protect teriflunomide chemical entity |
Highest |
| Pharmaceutical composition patents |
Cover tablets, excipients, or dosage forms |
Moderate, depending on claim scope |
| Method-of-use patents |
Cover treatment of relapsing MS or dosing regimens |
Variable |
| Manufacturing patents |
Protect synthesis or purification processes |
Usually limited against finished-dose competition |
| Pediatric exclusivity |
Adds six months to qualifying protection |
Temporary |
Sanofi and related entities pursued patent litigation against generic applicants that filed Abbreviated New Drug Applications with Paragraph IV certifications. Those certifications asserted that listed patents were invalid, unenforceable, or would not be infringed. The litigation created a delay mechanism, but it did not produce durable protection after the main patent estate reached expiry.
Which companies challenged Aubagio patents?
Generic applicants that challenged or sought approval for teriflunomide included major and specialty generic manufacturers such as Teva, Mylan or Viatris, Zydus, Dr. Reddy’s Laboratories, Torrent Pharmaceuticals, Alembic, and other applicants reflected in FDA approval records and federal litigation dockets.
The competitive process followed the standard Hatch-Waxman sequence:
- A generic applicant filed an ANDA.
- The applicant submitted a Paragraph IV certification against one or more listed patents.
- Sanofi or an affiliated patent holder initiated infringement litigation.
- The litigation created a potential 30-month stay of FDA approval, subject to statutory conditions.
- FDA approvals and commercial launches followed after patent expiry, settlement rights, or other resolution.
The number of filers increased launch pressure because multiple approved manufacturers can enter near the same time. That structure usually creates faster price erosion than a single first-filer launch.
What is the Orange Book status of teriflunomide?
Aubagio tablets were listed in the FDA Orange Book as the reference product for teriflunomide ANDAs. The Orange Book identifies approved drug products, therapeutic equivalence information, and listed patents and exclusivity data.[4]
The practical Orange Book analysis is:
- The reference product is Aubagio.
- Generic teriflunomide tablets can qualify for therapeutic-equivalence ratings when FDA requirements are met.
- Orange Book patent listings supported the Paragraph IV challenge process.
- Once listed-patent barriers expired or were otherwise cleared, FDA-approved generics could compete directly with Aubagio.
- Product-level approval does not guarantee commercial success; payer contracts, supply reliability, and launch pricing determine actual share capture.
Teriflunomide is a small molecule, so biosimilar regulation does not apply. Generic companies use the ANDA pathway, not the Biologics Price Competition and Innovation Act pathway.
What generic entry risks exist for teriflunomide?
Generic entry risk is high because the product has several characteristics associated with rapid erosion:
- It is an oral small molecule.
- The reference product has a straightforward tablet dosage form.
- Clinical substitution does not require physician retraining comparable to a complex biologic.
- Multiple manufacturers received or pursued approval.
- The branded product lost its central patent protection after a long commercial life.
- Multiple sclerosis payers have experience managing generic oral therapies.
The main residual barriers are manufacturing quality, supply continuity, regulatory compliance, pharmacovigilance, and the need to maintain consistent tablet production at both 7 mg and 14 mg strengths. These barriers can affect individual manufacturers but do not preserve the originator’s pricing power.
How did generic entry change the financial trajectory?
The U.S. generic launch changed Aubagio from a growth and cash-flow product into a declining residual asset. Sanofi’s 2023 results reflected a sharp reduction from the prior year, with the decline concentrated in the United States.
Base-case financial trajectory
| Period |
Brand economics |
Expected market structure |
| Before 2023 |
High-margin branded specialty medicine |
Sanofi-led |
| 2023 |
Rapid revenue decline |
Early generic competition |
| 2024-2025 |
Continued price and volume erosion |
Several generic suppliers |
| Later period |
Low branded contribution |
Generic-dominated market |
The most exposed revenue was U.S. revenue because the United States accounts for a disproportionate share of branded pharmaceutical profitability. International markets often experience slower generic penetration because of local patent rules, tender systems, reimbursement negotiations, and different substitution practices. Those markets can extend residual sales but rarely offset U.S. loss-of-exclusivity erosion.
Sanofi’s broader portfolio strategy also matters. The company has increasingly concentrated capital on vaccines, immunology, rare diseases, and specialty medicines with longer growth runways. Aubagio’s patent expiry reduced the company’s incentive to defend the product through major lifecycle investment.
How does teriflunomide compare with competing multiple sclerosis drugs?
| Drug |
Commercial position |
Competitive advantage |
Main pressure on teriflunomide |
| Teriflunomide |
Generic-exposed oral therapy |
Once-daily dosing and low cost |
Lower price and generic substitution |
| Dimethyl fumarate |
Oral MS therapy with generic competition |
Broad physician familiarity |
Competes for similar oral-treatment population |
| Fingolimod |
Oral high-efficacy therapy with generic versions |
Established efficacy in relapsing MS |
Generic pricing and safety monitoring |
| Ocrelizumab |
Infused anti-CD20 biologic |
High efficacy and strong specialist adoption |
Greater efficacy positioning |
| Ofatumumab |
Self-administered anti-CD20 biologic |
High efficacy and home administration |
Pulls patients toward newer agents |
| Interferon beta products |
Injectable disease-modifying therapies |
Long clinical history |
Administration burden and tolerability |
Teriflunomide’s commercial defense is strongest in patients who prioritize oral convenience, established safety experience, or lower cost. Its defense is weaker in treatment strategies that prioritize high efficacy for patients with active or aggressive disease.
What manufacturing and intellectual-property barriers remain?
The core molecule is no longer a strong exclusivity platform in the United States. Remaining barriers are operational rather than primarily patent-based.
Manufacturing barriers
Manufacturers must manage:
- Reproducible synthesis and impurity control.
- Tablet content uniformity at both dose strengths.
- Stability and packaging requirements.
- FDA inspection and quality-system compliance.
- Reliable API sourcing.
- Post-approval change controls.
- Pharmacovigilance and labeling compliance.
Process patents may create targeted barriers if a manufacturer relies on a protected route, but a generic company can often design around a process claim. Manufacturing patents therefore have less blocking power than a broad composition patent.
Geographic coverage
Patent and regulatory exposure differs by jurisdiction. The United States experienced the clearest revenue shock because of large branded sales and rapid ANDA competition. Europe and other markets may show different timing based on national patent enforcement, reference pricing, tender procurement, and substitution rules.
A global teriflunomide valuation should separate:
- U.S. branded and generic sales.
- European national-market erosion.
- Emerging-market volume growth.
- Government tender exposure.
- Local manufacturing and registration requirements.
- Currency and reimbursement effects.
How strong is the teriflunomide patent estate now?
The estate is commercially weak for maintaining branded U.S. pricing. The core patent protection that supported Aubagio has expired or reached the end of its effective commercial life, and secondary patents have limited ability to prevent broad generic substitution.
| Patent-estate factor |
Assessment |
| Core molecule protection |
Expired or no longer commercially blocking in the U.S. |
| Formulation protection |
Limited ability to block standard tablets |
| Method-of-use protection |
Potentially narrower and easier to design around |
| Manufacturing protection |
Relevant to specific processes, not necessarily the finished product |
| Regulatory exclusivity |
Completed |
| Generic substitution risk |
High |
| Branded pricing durability |
Low |
What is the outlook for teriflunomide revenue?
Teriflunomide revenue will increasingly reflect generic volume rather than originator economics. Sanofi’s Aubagio sales are likely to remain well below the pre-expiry peak, with the steepest decline occurring during the first two years after U.S. generic launch.
The generic market can remain commercially attractive where:
- Several suppliers maintain stable API access.
- The product has predictable chronic-use demand.
- Payers favor low-cost oral therapy.
- Manufacturing yields support competitive pricing.
- Regulatory approvals extend to additional countries.
For investors, the key valuation question is not whether teriflunomide remains clinically relevant. It does. The question is which manufacturers can obtain durable volume and acceptable gross margins after price compression.
Key Takeaways
- Teriflunomide is the active ingredient in Sanofi’s Aubagio, an oral therapy for relapsing multiple sclerosis.
- Aubagio generated approximately €2 billion annually before U.S. generic entry.
- Sanofi reported a substantial sales decline in 2023 after generic teriflunomide became available.
- U.S. composition-patent protection reached the end of its commercial life in 2023.
- Multiple generic manufacturers challenged Aubagio patents or pursued ANDA approval.
- Teriflunomide is subject to generic, not biosimilar, competition.
- Secondary formulation, method-of-use, and manufacturing patents have limited ability to preserve branded pricing.
- The product remains clinically relevant, but future value is concentrated in low-cost generic volume.
- Ocrelizumab and ofatumumab create ongoing efficacy-based competitive pressure.
- Residual international sales may persist longer than U.S. branded sales, but are unlikely to restore peak revenue.
Frequently Asked Questions
Is teriflunomide still commercially important after Aubagio patent expiry?
Yes. The molecule remains an established oral multiple sclerosis therapy, but the commercial value has shifted from Sanofi’s branded product to generic manufacturers.
Does teriflunomide have biosimilar competition?
No. Teriflunomide is a chemically synthesized small molecule. Competitors use the FDA ANDA generic-drug pathway.
What caused Aubagio sales to fall in 2023?
The primary cause was U.S. generic entry after the end of core patent protection and related exclusivity barriers. Generic substitution reduced both branded volume and net pricing.
Can method-of-use patents block generic teriflunomide?
They can create litigation exposure if valid and infringed, but narrow method-of-use claims generally provide less protection than a broad composition patent and may be addressed through label strategies or design-around arguments.
Which products compete most directly with teriflunomide?
The closest oral competitors are generic dimethyl fumarate and generic fingolimod. Ocrelizumab and ofatumumab compete at the treatment-strategy level through higher-efficacy anti-CD20 mechanisms.
References
- Sanofi. (2023). 2022 annual report. Sanofi.
- Sanofi. (2024). 2023 annual report. Sanofi.
- United States Patent and Trademark Office. (2008). U.S. Patent No. 7,332,521: Teriflunomide and related compounds.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- U.S. Food and Drug Administration. (2012). Aubagio prescribing information. FDA.
- U.S. Food and Drug Administration. (2023). Drug approvals and generic-drug database records for teriflunomide tablets. FDA.
